The abstract is read at the publisher; the summary is JClub's.
An ornithine-linked fecal metabolomic signature identifies colorectal tumor development in CRC mouse models and patients, enabling an EcN-based ornithine-responsive bioluminescent reporter for detection.
- Why it matters: CRC remains highly prevalent, and there is a need for non-invasive biomarkers and targeted, locally acting therapies that can be translated beyond preclinical settings.
- What they did: The study used comprehensive fecal metabolomics in CRC mouse models and patients to pinpoint ornithine, then engineered an E. coli Nissle 1917 bioluminescent reporter responsive to ornithine for tumor detection.
- The result: A probiotic system that locally releases Dickkopf 3 (DKK3) suppressed tumor growth and improved survival across multiple preclinical models, with efficacy confirmed in CRC patient-derived organoids and a patient-derived xenograft model.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.